Abstract 38P
Background
Immune Checkpoint Inhibitors (ICIs) have substantially improved the prognosis of metastatic melanoma. However, not all patients benefit equally. To optimize patient selection for ICIs and minimize immune-related toxicity in those with a low likelihood of response, it is essential to identify predictive biomarkers. Our study assessed the association between certain patient characteristics and response to ICIs, progression-free survival (PFS), and overall survival (OS).
Methods
In this retrospective, observational study, we included 49 patients with metastatic melanoma treated with Pembrolizumab or with Nivolumab + Ipilimumab. Collected parameters included sex, age, BRAF V600E mutation status, localization of metastases, baseline lactate dehydrogenase (LDH) and neutrophil to lymphocyte ratio (NLR), best overall response (bOR) achieved, development and type of immune related adverse events (irAEs), dates of progression and death. All statistical analyses were performed using Jamovi, version 2.5.4.
Results
Most patients (57.1%) received Nivolumab + Ipilimumab, with an Overall Response Rate (ORR) of 35.7%, while ORR for Pembrolizumab was 28.5%. For the entire cohort, median PFS and OS were 9.1 months and 21 months, respectively. We found a significant association between the response to ICIs and irAEs, with a relative risk (RR) of 2.93 (p= 0.01). Cutaneous irAEs, including vitiligo, occurred in 52.4% of patients and were associated with a higher RR of 3.45 (p = 0.003). There was no association between response to ICIs and LDH, NLR, sex, age or BRAF status. Patients with elevated LDH (>245 U/L) had significantly shorter OS than those with normal LDH, with HR: 3.26 (95% CI: 1.16-9.17), p < 0.05. Similarly, patients with elevated NLR (cut-off values: 3.46 for PFS, 4.13 for OS) had significantly shorter PFS and OS than those with low NLR (p < 0.05), with corresponding hazard ratios of 1.23 (95% CI: 1.03-1.47) for PFS and 1.34 (95% CI: 1.09-1.64) for OS.
Conclusions
The development of irAEs, particularly cutaneous irAEs, may serve as an indicator of response to ICIs in metastatic melanoma patients. Baseline LDH and NLR levels have prognostic significance, but are not predictive of response to ICIs.
Editorial acknowledgement
During the preparation of this work the author(s) used ChatGPT in order to rephrase sentences, make them shorter/ more concise in order to better express the meaning and fit inside the character limit. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract